August 20, 2014 12:18 PM ET

Capital Markets

Company Overview of MedImmune Ventures, Inc.

Executive Profile

Peter S. Greenleaf

Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee, Sucampo Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 2 Board Members in 2 different organizations across 7 different industries.

See Board Relationships
44--

Background

Mr. Peter S. Greenleaf has been the Chief Executive Officer of Sucampo Pharmaceuticals, Inc. since March 03, 2014. Mr. Greenleaf served as Chief Executive Officer of Histogenics Corporation from June 10, 2013 to May 2014 and served as its President. Mr. Greenleaf served as President of MedImmune, LLC (also known as MedImmune, Inc.). Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, where he ...

Corporate Headquarters

One MedImmune Way
Gaithersburg, Maryland 20878

United States

Phone: 301-398-3000
Fax: 301-398-8170

Board Members Memberships

Former Director
Director
Former Chief Executive Officer and Director
Former Director
2010-N/A
Former Director
2014-Present
Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee

Education

MBA
Saint Joseph's University
BA
Western Connecticut State University

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$831.2K
Friedhelm Blobel Ph.D.Chief Executive Officer, President, Executive Director and Member of Business Development Committee
SciClone Pharmaceuticals, Inc.
$550.0K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$535.6K
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals Inc.
$621.0K
A. J. Kazimi MBAFounder, Chairman, Chief Executive Officer and President
Cumberland Pharmaceuticals, Inc.
$620.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MedImmune Ventures, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.